Atrium Therapeutics Doses First Patient in ATR 1072 Phase 1/2 Trial
Atrium Therapeutics said it dosed the first patient in its Phase 1/2 trial of ATR 1072.
Related stories
Samsung SDI to Supply Batteries to Jupiter Power
Samsung SDI says it will supply batteries to Jupiter Power for three years starting in 2029.
M impact | EQUITY | Nov 15, 2026, 11:18 PM UTC
More Than 10,000 US Flights Affected for Third Day
US air travel disruptions continued Sunday, with Transportation Secretary Sean Duffy predicting a return to normal by Monday as airlines worked to restore schedules.
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Thousands of US Flights Canceled, Delayed for Third Day in a Row
M impact | EQUITY | Nov 15, 2026, 11:11 PM UTC
Boeing-Lockheed Rocket Fails Mid-Flight, Destroying Amazon Satellites
M impact | EQUITY | Nov 15, 2026, 11:09 PM UTC
Samsung SDI Wins 16 GWh Battery Order From Jupiter Power
Samsung SDI's U.S. subsidiary signed an order for 16 GWh of batteries from Jupiter Power.
M impact | EQUITY | Nov 15, 2026, 11:05 PM UTC
Intel shareholders sue after 29% stock plunge
Intel shareholders sued the company following a 29% stock plunge, Reuters reported.
M impact | EQUITY | Nov 15, 2026, 11:03 PM UTC